{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:58:17Z","timestamp":1790780297408,"version":"4.1.0"},"reference-count":29,"publisher":"American Academy of Pediatrics (AAP)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015,2,1]]},"abstract":"<jats:sec>\n                  <jats:title>BACKGROUND AND OBJECTIVES:<\/jats:title>\n                  <jats:p>Migraine headache is a common pediatric complaint among emergency department (ED) patients. There are limited trials on abortive therapies in the ED. The objective of this study was to apply a comparative effectiveness approach to investigate acute medication regimens for the prevention of ED revisits.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>METHODS:<\/jats:title>\n                  <jats:p>Retrospective study using administrative data (Pediatric Health Information System) from 35 pediatric EDs (2009\u20132012). Children aged 7 to 18 years with a principal diagnosis of migraine headache were studied. The primary outcome was a revisit to the ED within 3 days for discharged patients. The primary analysis compared the treatment regimens and individual medications on the risk for revisit.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>RESULTS:<\/jats:title>\n                  <jats:p>The study identified 32\u2009124 children with migraine; 27\u2009317 (85%) were discharged, and 5.5% had a return ED visit within 3 days. At the index visit, the most common medications included nonopioid analgesics (66%), dopamine antagonists (50%), diphenhydramine (33%), and ondansetron (21%). Triptans and opiate medications were administered infrequently (3% each). Children receiving metoclopramide had a 31% increased odds for an ED revisit within 3 days compared with prochlorperazine. Diphenhydramine with dopamine antagonists was associated with 27% increased odds of an ED revisit compared with dopamine antagonists alone. Children receiving ondansetron had similar revisit rates to those receiving dopamine antagonists.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>CONCLUSIONS:<\/jats:title>\n                  <jats:p>The majority of children with migraines are successfully discharged from the ED and only 1 in 18 required a revisit within 3 days. Prochlorperazine appears to be superior to metoclopramide in preventing a revisit, and diphenhydramine use is associated with increased rates of return.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1542\/peds.2014-2432","type":"journal-article","created":{"date-parts":[[2015,1,27]],"date-time":"2015-01-27T01:35:06Z","timestamp":1422322506000},"page":"232-238","source":"Crossref","is-referenced-by-count":61,"title":["A Comparison of Acute Treatment Regimens for Migraine in the Emergency Department"],"prefix":"10.1542","volume":"135","author":[{"given":"Richard G.","family":"Bachur","sequence":"first","affiliation":[{"name":"Division of Emergency Medicine, Boston Children\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael C.","family":"Monuteaux","sequence":"additional","affiliation":[{"name":"Division of Emergency Medicine, Boston Children\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark I.","family":"Neuman","sequence":"additional","affiliation":[{"name":"Division of Emergency Medicine, Boston Children\u2019s Hospital and Harvard Medical School, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"417","published-online":{"date-parts":[[2015,2,1]]},"reference":[{"issue":"2","key":"2021120907034031700_B1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ncl.2008.11.003","article-title":"Pediatric migraine.","volume":"27","author":"Lewis","year":"2009","journal-title":"Neurol Clin"},{"issue":"2","key":"2021120907034031700_B2","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1468-2982.2004.00652.x","article-title":"Quality of life in paediatric migraine: characterization of age-related effects using PedsQL 4.0.","volume":"24","author":"Powers","year":"2004","journal-title":"Cephalalgia"},{"issue":"2","key":"2021120907034031700_B3","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/head.12251","article-title":"Quality of life and health-related disability in children with migraine.","volume":"54","author":"Ferracini","year":"2014","journal-title":"Headache"},{"issue":"4","key":"2021120907034031700_B4","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.pediatrneurol.2012.06.001","article-title":"Treatment of pediatric migraine in the emergency room.","volume":"47","author":"Gelfand","year":"2012","journal-title":"Pediatr Neurol"},{"issue":"1","key":"2021120907034031700_B5","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2009-2337","article-title":"Treatment of children with migraine in emergency departments: national practice variation study.","volume":"126","author":"Richer","year":"2010","journal-title":"Pediatrics"},{"issue":"3","key":"2021120907034031700_B6","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.ajem.2010.12.020","article-title":"Prochlorperazine in children with migraine: a look at its effectiveness and rate of akathisia.","volume":"30","author":"Trottier","year":"2012","journal-title":"Am J Emerg Med"},{"issue":"2","key":"2021120907034031700_B7","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/S0196-0644(03)00716-9","article-title":"Treatment of pediatric migraine headaches: a randomized, double-blind trial of prochlorperazine versus ketorolac.","volume":"43","author":"Brousseau","year":"2004","journal-title":"Ann Emerg Med"},{"issue":"8","key":"2021120907034031700_B8","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1177\/0883073810397631","article-title":"Treatment of pediatric status migrainosus: can we prevent the \u201cbounce back\u201d?","volume":"26","author":"Legault","year":"2011","journal-title":"J Child Neurol"},{"issue":"5","key":"2021120907034031700_B9","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1111\/j.1526-4610.2007.00782.x","article-title":"Emergency department management of acute migraine in children in Canada: a practice variation study.","volume":"47","author":"Richer","year":"2007","journal-title":"Headache"},{"key":"2021120907034031700_B10"},{"issue":"5","key":"2021120907034031700_B11","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2013-1614","article-title":"Narrow vs broad-spectrum antimicrobial therapy for children hospitalized with pneumonia.","volume":"132","author":"Williams","year":"2013","journal-title":"Pediatrics"},{"issue":"6","key":"2021120907034031700_B12","doi-asserted-by":"crossref","DOI":"10.1542\/peds.107.6.e99","article-title":"Deaths attributed to pediatric complex chronic conditions: national trends and implications for supportive care services.","volume":"107","author":"Feudtner","year":"2001","journal-title":"Pediatrics"},{"key":"2021120907034031700_B13"},{"issue":"12","key":"2021120907034031700_B14","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1212\/01.WNL.0000147332.41993.90","article-title":"Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society.","volume":"63","author":"Lewis","year":"2004","journal-title":"Neurology"},{"issue":"5","key":"2021120907034031700_B15","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/PEC.0b013e31816ed047","article-title":"Treatment of children with migraine in the emergency department: a qualitative systematic review.","volume":"24","author":"Bailey","year":"2008","journal-title":"Pediatr Emerg Care"},{"issue":"4","key":"2021120907034031700_B16","doi-asserted-by":"crossref","DOI":"10.1542\/peds.107.4.e62","article-title":"Tolerability and effectiveness of prochlorperazine for intractable migraine in children.","volume":"107","author":"Kabbouche","year":"2001","journal-title":"Pediatrics"},{"issue":"3","key":"2021120907034031700_B17","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/jamapediatrics.2013.872","article-title":"Migraine therapeutics in adolescents: a systematic analysis and historic perspectives of triptan trials in adolescents.","volume":"167","author":"Sun","year":"2013","journal-title":"JAMA Pediatr"},{"issue":"3","key":"2021120907034031700_B18","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/head.12042","article-title":"Effectiveness of standardized combination therapy for migraine treatment in the pediatric emergency department.","volume":"53","author":"Leung","year":"2013","journal-title":"Headache"},{"key":"2021120907034031700_B19","article-title":"Current management of migraine in US emergency departments: An analysis of the National Hospital Ambulatory Medical Care Survey [published online ahead of print June 19, 2014].","author":"Friedman","journal-title":"Cephalalgia"},{"issue":"5","key":"2021120907034031700_B20","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0196-0644(95)70001-3","article-title":"Randomized, placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache.","volume":"26","author":"Coppola","year":"1995","journal-title":"Ann Emerg Med"},{"issue":"2","key":"2021120907034031700_B21","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1067\/mem.2001.113032","article-title":"Diphenhydramine for the prevention of akathisia induced by prochlorperazine: a randomized, controlled trial.","volume":"37","author":"Vinson","year":"2001","journal-title":"Ann Emerg Med"},{"issue":"2","key":"2021120907034031700_B22","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jemermed.2008.08.012","article-title":"Clinical outcomes of children treated with intravenous prochlorperazine for migraine in a pediatric emergency department.","volume":"39","author":"Trottier","year":"2010","journal-title":"J Emerg Med"},{"issue":"1","key":"2021120907034031700_B23","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1212\/WNL.48.1.103","article-title":"Ibuprofen or acetaminophen for the acute treatment of migraine in children: a double-blind, randomized, placebo-controlled, crossover study.","volume":"48","author":"H\u00e4m\u00e4l\u00e4inen","year":"1997","journal-title":"Neurology"},{"issue":"4","key":"2021120907034031700_B24","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1468-2982.2008.01546.x","article-title":"Early vs. non-early intervention in acute migraine\u2014\u201cAct when Mild (AwM).\u201d A double-blind, placebo-controlled trial of almotriptan.","volume":"28","author":"Goadsby","year":"2008","journal-title":"Cephalalgia"},{"issue":"3","key":"2021120907034031700_B25","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0735-6757(02)42256-5","article-title":"A prospective double-blind study of nasal sumatriptan versus IV ketorolac in migraine.","volume":"21","author":"Meredith","year":"2003","journal-title":"Am J Emerg Med"},{"issue":"7","key":"2021120907034031700_B26","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1212\/01.wnl.0000238179.79888.44","article-title":"A randomized trial of rizatriptan in migraine attacks in children.","volume":"67","author":"Ahonen","year":"2006","journal-title":"Neurology"},{"issue":"6","key":"2021120907034031700_B27","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2011-2455","article-title":"Randomized trial of sumatriptan and naproxen sodium combination in adolescent migraine.","volume":"129","author":"Derosier","year":"2012","journal-title":"Pediatrics"},{"issue":"2","key":"2021120907034031700_B28","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1542\/peds.2007-0085","article-title":"Efficacy of zolmitriptan nasal spray in adolescent migraine.","volume":"120","author":"Lewis","year":"2007","journal-title":"Pediatrics"},{"issue":"5","key":"2021120907034031700_B29","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1542\/peds.106.5.989","article-title":"A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents.","volume":"106","author":"Winner","year":"2000","journal-title":"Pediatrics"}],"container-title":["Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/135\/2\/232\/1058274\/peds_2014-2432.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/publications.aap.org\/pediatrics\/article-pdf\/135\/2\/232\/1058274\/peds_2014-2432.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T01:25:05Z","timestamp":1639099505000},"score":1,"resource":{"primary":{"URL":"https:\/\/publications.aap.org\/pediatrics\/article\/135\/2\/232\/33499\/A-Comparison-of-Acute-Treatment-Regimens-for"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2,1]]},"references-count":29,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2015,2,1]]},"published-print":{"date-parts":[[2015,2,1]]}},"URL":"https:\/\/doi.org\/10.1542\/peds.2014-2432","relation":{},"ISSN":["0031-4005","1098-4275"],"issn-type":[{"value":"0031-4005","type":"print"},{"value":"1098-4275","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,2,1]]}}}